Rena Therapeutics Inc. is pleased to announce the launch of the “HDO Free Trial & Collaborative Research Call 2026,” accepting research proposals from October 1 through October 31, 2026.
This program invites researchers from universities, research institutions, pharmaceutical companies, and biotechnology companies to evaluate our proprietary Heteroduplex Oligonucleotide (HDO) technology in your own in vivo experimental models. By combining your targets and experimental systems with HDO technology, we aim to explore novel therapeutic approaches and potential drug discovery opportunities.
For full application guidelines and online submission, please visit our dedicated campaign website.
[HDO Free Trial & Collaborative Research Call 2026 Special Page] ttps://www.